From the Editor

Amid high expectations for a COVID-19 vaccine, biopharma readies production capacity, weighs external pressures.

Time sure flies, except when you are waiting for something to happen.

The BioPharm International Editorial Advisory Board shares their professional expertise in bioprocessing topics to help shape editorial content and review peer-review papers.

Achieving herd immunity will require testing, data, a vaccine, and public support.

As the coronavirus pandemic unfolds, the bio/pharma industry must practice science over hype.

Emergency actions to protect patients and the drug supply may have long-term implications.

Bio/pharma researchers mobilize to diagnose and treat patients in pandemic threat.

The promise of new therapies is tempered by the need for affordability, safety, and ethics.

Nearly four decades after the first diagnosis, the fight to treat HIV/AIDs continues.

FDA report says drug shortages are underappreciated and patients pay a price.

Climbing out of a reputation hole can start with adopting a quality culture.

Half a century after man first walked on the moon, space-based science is exploring benefits for Planet Earth.

FDA and USP take sides in debate on biologic drug standards.

FDA’s annual manufacturing report card shows more quality compliance is needed.

Pharma delivers a positive message with renewed efforts to eradicate malaria.

Promoting patient compliance with drug regimens extends beyond the formulation laboratory.

Do patients get what they pay for when they demand cheaper drugs?

Biosimilars, pricing strategies, and technology investments will influence growth in spending on drugs.

Pricing pressures, investment volatility, and government disfunction greet Biopharma in 2019.

Innovation may capture headlines, but quality programs are the foundation to biopharma success.

After 30 years of biologic-drug advances, the industry and patients still have a lot to learn.

By minding gaps in industry knowledge, bio/pharma companies can avoid development pitfalls.

While technology promises advances for healthcare, a skilled workforce is needed to deliver on the potential.

More diversified therapies and tighter payer budgets will challenge bio/pharma companies to think outside the industry.

FDA enforcement efforts and drug approvals trend upward.